RGNX - REGENXBIO Inc Stock Price, Fair Value and News

$7.87+0.47 (+6.35%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RGNX Price Action

Last 7 days

-12.6%

Last 30 days

-22.8%

Last 90 days

-31.7%

Trailing 12 Months

-60.3%

RGNX RSI Chart

RGNX Valuation

Market Cap

366.6M

Price/Earnings (Trailing)

-1.54

Price/Sales (Trailing)

4.35

EV/EBITDA

-1.69

Price/Free Cashflow

-1.98

RGNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RGNX Fundamentals

RGNX Revenue

Revenue (TTM)

84.3M

Rev. Growth (Yr)

-16.31%

Rev. Growth (Qtr)

8.53%

RGNX Earnings

Earnings (TTM)

-238.8M

Earnings Growth (Yr)

3.67%

Earnings Growth (Qtr)

-12.47%

RGNX Profitability

EBT Margin

-312.65%

Return on Equity

-79.23%

Return on Assets

-46%

Free Cashflow Yield

-50.39%

RGNX Investor Care

Shares Dilution (1Y)

12.62%

Diluted EPS (TTM)

-5.02

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	86.7M	89.0M	84.3M	0
2023	109.6M	97.0M	99.4M	90.2M
2022	473.7M	484.3M	480.0M	112.7M
2021	155.8M	161.3M	93.1M	470.3M
2020	52.0M	60.7M	144.9M	154.6M
2019	172.7M	126.9M	81.1M	35.2M
2018	142.3M	175.8M	179.8M	218.5M
2017	4.7M	8.8M	10.0M	10.4M
2016	7.3M	8.3M	7.3M	4.6M
2015	3.8M	3.6M	4.3M	7.6M
2014	6.1M	6.1M	6.1M	6.1M
2013	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

CEO	Mr. Kenneth T. Mills
WEBSITE	regenxbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	401

REGENXBIO Inc Frequently Asked Questions

What is the ticker symbol for REGENXBIO Inc? What does RGNX stand for in stocks?

RGNX is the stock ticker symbol of REGENXBIO Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REGENXBIO Inc (RGNX)?

As of Tue Dec 24 2024, market cap of REGENXBIO Inc is 366.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGNX stock?

You can check RGNX's fair value in chart for subscribers.

Is REGENXBIO Inc a good stock to buy?

The fair value guage provides a quick view whether RGNX is over valued or under valued. Whether REGENXBIO Inc is cheap or expensive depends on the assumptions which impact REGENXBIO Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGNX.

What is REGENXBIO Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, RGNX's PE ratio (Price to Earnings) is -1.54 and Price to Sales (PS) ratio is 4.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGNX PE ratio will change depending on the future growth rate expectations of investors.